» Articles » PMID: 32862760

Effect of Renal Denervation on Catecholamines and the Renin-angiotensin-aldosterone System

Overview
Publisher Sage Publications
Specialty Physiology
Date 2020 Sep 1
PMID 32862760
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The effect of renal sympathetic denervation (RDN) on neurohormonal responses is largely unknown. We aimed to assess the effect of RDN on the renin-angiotensin-aldosterone system (RAAS) and endogenous catecholamines.

Methods: A total of 60 patients with hypertension underwent RDN and remained on a stable antihypertensive drug regimen. Samples for plasma aldosterone, plasma renin and urine (nor)metanephrine were collected at baseline and at 6 months post procedure. Ambulatory blood pressure (BP) recordings were obtained at baseline and at 6 months post procedure.

Results: Mean age was 64±9 years, and 30/60 patients were male. At 6 months, average daytime systolic and diastolic ambulatory BP decreased by 10 and 6 mmHg, respectively (<0.001). No significant change was observed in plasma aldosterone (median=248.0 pmol/L (interquartile range (IQR) 113.3-369.5 pmol/L) vs. median=233.0 pmol/L (IQR 110.3-360.8 pmol/L); =0.66); renin (median=19.5 µIU/mL (IQR 6.8-119.5 µIU/mL) vs. median=14.3 µIU/mL (IQR 7.2-58.0 µIU/mL); =0.32), urine metanephrine (median=0.46 µmol/L (IQR 0.24-0.77 µmol/L) vs. median=0.46 µmol/L (IQR 0.22-0.88 µmol/L); =0.75) and normetanephrine (median=1.41 µmol/L (IQR 0.93-2.00 µmol/L vs. median =1.56 (IQR 0.74-2.50 µmol/L); =0.58) between baseline and 6 months, respectively. No correlation was found between the decrease in mean systolic daytime BP and changes in RAAS hormones or endogenous catecholamines.

Conclusion: Despite significant reductions in ambulatory BP, RDN did not result in a significant change in endogenous catecholamines or in RAAS hormones at 6 months.

Citing Articles

Renal denervation for hypertensive heart disease and atrial fibrillation.

Shinohara K Hypertens Res. 2024; 47(10):2665-2670.

PMID: 38877310 DOI: 10.1038/s41440-024-01755-y.


Effects of catheter-based renal denervation on renin-aldosterone system, catecholamines, and electrolytes: A systematic review and meta-analysis.

Yang X, Lin L, Zhang Z, Chen X J Clin Hypertens (Greenwich). 2022; 24(12):1537-1546.

PMID: 36321724 PMC: 9731592. DOI: 10.1111/jch.14590.


Catheter-based renal sympathetic nerve denervation on hypertension management outcomes.

Singh S, Varghese K, Qureshi F, Anderson M, Foxworth J, Knuepfer M World J Radiol. 2022; 14(7):238-248.

PMID: 36160631 PMC: 9350608. DOI: 10.4329/wjr.v14.i7.238.


Present Evidence of Determinants to Predict the Efficacy of Renal Denervation.

Zhou H, Xu Y, Chen W, Wang L, Du H, Liu H Int J Hypertens. 2022; 2022:5694127.

PMID: 35992203 PMC: 9391193. DOI: 10.1155/2022/5694127.


Renal denervation does not affect hypertension or the renin-angiotensin system in a rodent model of juvenile-onset polycystic kidney disease: clinical implications.

Li S, Hildreth C, Rahman A, Barton S, Wyse B, Lim C Sci Rep. 2021; 11(1):14286.

PMID: 34253766 PMC: 8275789. DOI: 10.1038/s41598-021-93575-0.


References
1.
Hering D, Lambert E, Marusic P, Walton A, Krum H, Lambert G . Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2012; 61(2):457-64. DOI: 10.1161/HYPERTENSIONAHA.111.00194. View

2.
Azizi M, Schmieder R, Mahfoud F, Weber M, Daemen J, Davies J . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018; 391(10137):2335-2345. DOI: 10.1016/S0140-6736(18)31082-1. View

3.
Peaston R, Weinkove C . Measurement of catecholamines and their metabolites. Ann Clin Biochem. 2004; 41(Pt 1):17-38. DOI: 10.1258/000456304322664663. View

4.
Hong M, Li X, Chen D, Ruan C, Xu J, Chen J . Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension. Oncotarget. 2016; 7(42):67828-67840. PMC: 5356522. DOI: 10.18632/oncotarget.12182. View

5.
Wasilewski G, Przybylowski P, Wilusz M, Sztefko K, Janik L, Koc-Zorawska E . High-performance Liquid Chromatography Measured Metabolites of Endogenous Catecholamines and Their Relations to Chronic Kidney Disease and High Blood Pressure in Heart Transplant Recipients. Transplant Proc. 2016; 48(5):1751-5. DOI: 10.1016/j.transproceed.2016.02.059. View